03 Jun 2019 | News

QUOTED. 3 June 2019. US FDA.

by

An expert panel recommended the US Food and Drug Administration downclassify certain absorbable collagen hemostatic devices despite concerns there isn't enough clinical data to support their safety and efficacy. See what the agency said in a briefing document here.

"In accordance with the 6-year rule, FDA considered data contained in two original PMAs approved for absorbable collagen-based hemostatic devices six or more years before the date of this panel to support our proposed classification recommendation." –US Food & Drug Administration

• Find out more: <u>Experts Recommend Down-Classifying Absorbable Collagen Hemostatic Devices</u>
<u>Despite Data Doubts</u>

<u>Click here</u> for a free trial of Medtech Insight